Sinusitis

Oct 08, 2008 - In This Report

• Highlights
• Introduction
• Causes
• Risk Factors
• Symptoms
• Complications
• Diagnosis
• Prevention
• Treatment for Acute Sinusit...
• Treatment for Chronic Sinus...
• Surgery
• Resources
• References

HEALTH GUIDE REFERENCE FROM A.D.A.M Highlights Drug Restriction In February 2007, the FDA announced that the antibiotic telithromycin (Ketek) should no longer be used for treatment of acute bacterial sinusitis. In June 2006, the FDA reported that several people had died of liver damage after taking this drug. Telithromycin is now only approved for treatment of community-acquired pneumonia. - 0 Comments

Back pain and sciatica

Oct 08, 2008 - In This Report

• Highlights
• Introduction
• Causes
• Risk Factors
• Diagnosis
• Medications
• Complementary and Alternati...
• Exercise and Physical Thera...
• Surgery
• Other Treatments
• Specific Treatment for Acut...
• Specific Treatment for Chro...
• Prognosis
• Complications
• Prevention
• Resources
• References

HEALTH GUIDE REFERENCE FROM A.D.A.M Highlights Surgery Kyphoplasty, a surgical technique used to treat spinal fractures, does not improve a person's back pain or quality of life, according to a review published in 2006 by a nonprofit health services research agency. Kyphoplasty should only be done if bed rest, medicines, and physical therapy do not relieve back pain. Ultrasound Therapeutic ultrasound uses sound waves to deliver gentle vibrations to an area of the body. - 0 Comments

Urinary incontinence

Oct 08, 2008 - In This Report

• Highlights
• Introduction
• Stress Incontinence
• Urge Incontinence
• Overflow Incontinence
• Functional Incontinence
• Risk Factors
• Diagnosis
• Prognosis
• Treatment
• Lifestyle Changes
• Other Treatments
• Behavioral Treatments
• Medications
• Surgery
• Other Procedures
• Catheters and Collection De...
• Resources
• References

HEALTH GUIDE REFERENCE FROM A.D.A.M Highlights Sling Procedure Versus Burch Colposuspension The sling procedure is better than Burch colposuspension in treating stress incontinence but may cause more post-operative urinary complications, according to results from an important 2007 New England Journal of Medicine study. In the first large-scale clinical trial to directly compare these two types of surgery, 47% of women who underwent the sling procedure had no urinary incontinence 2 years after surgery, compared with 38% of women who received the Burch procedure. However, 63% of women who had the sling procedure (and 47% of women who underwent the Burch procedure) experienced urinary tract infections following surgery. - 0 Comments

Benign prostatic hyperplasia

Oct 08, 2008 - In This Report

• Highlights
• Introduction
• Symptoms
• Causes of Benign Prostatic ...
• Causes of Lower Urinary Tra...
• Risk Factors
• Complications
• Diagnostic Tests
• Treatment
• Lifestyle Changes
• Medications
• Other Treatments
• Resources
• References

HEALTH GUIDE REFERENCE FROM A.D.A.M Highlights Self-Management for Benign Prostatic Hyperplasia (BPH) Men who receive training in lifestyle and behavioral approaches may be able to successfully manage BPH without drugs or surgery, suggests a 2007 study in the British Medical Journal. Men in the study were trained to self-manage their lower urinary tract symptoms (LUTS), a condition that often accompanies BPH. Self-management approaches included limiting daily fluid intake, avoiding caffeine and alcohol, and urinating at least once every 3 hours. - 0 Comments

Hepatitis

Oct 08, 2008 - In This Report

• Highlights
• Introduction
• Diagnosis
• Hepatitis A
• Hepatitis B and D
• Hepatitis C
• Autoimmune Hepatitis
• Symptom Management
• Outlook
• Resources
• References

HEALTH GUIDE REFERENCE FROM A.D.A.M Highlights Drug Approvals

• In 2006, the FDA approved telbivudine (Tyzeka), a new type of nucleoside analog drug, for treatment of chronic hepatitis B. There are now six drugs approved for hepatitis B treatment.
• In 2007, the FDA approved HepaGam B, an intravenous immune globulin drug, for preventing hepatitis B recurrence following liver transplantation.

Drug Warning In 2007, the FDA revised the prescribing label for entecavir (Baraclude), a drug used to treat hepatitis B. The new label advises against using entacavir in patients infected with both hepatitis B and HIV who are not receiving antiretroviral (anti-HIV) therapy. - 0 Comments